TickerGuard
Buy Day today: Poor (44) Weak market breadth · major macro event coming up
NTLA

Intellia Therapeutics Inc

Healthcare · Biotechnology

12.30$ -2.8% vs. previous close Closing price · As of: Sep 23, 2026

Statements

Income Statement

Intellia Therapeutics Inc (NTLA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 7.7 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement NTLA
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
12 -1.9 29 7.0 9.1 13 17 14 14 23 15 7.7 60
2.3 2.5 2.5 2.6 109 117 – 81 79 6.0 2.2 – –
9.7 -4.4 26 4.4 -100 -104 17 -66 -65 17 13 7.7 -28
114 109 109 112 123 117 108 97 95 89 81 83 347
29 29 31 32 31 32 29 27 31 33 35 38 136
141 136 140 143 45 32 137 44 46 116 113 120 396
-131 -140 -114 -139 -145 -136 -121 -110 -111 -99 -101 -113 -423
– 8.8 – – – – – – – – – – –
-122 -132 -107 -147 -136 -129 -114 -101 -101 -96 -96 -107 -400
-15 41 2.5 – – – – – – – – – –
-122 -132 -107 -147 -136 -129 -114 -101 -101 -96 -96 -107 -400
-120 -130 -105 -144 -133 -126 -112 -99 -96 -95 -94 -105 -390

LTM = last twelve months (sum of the four most recent quarters).

Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?